Korsana Biosciences Inc. is a biotechnology company discovering and developing novel therapies to reduce the burden of neurodegenerative diseases. Its lead program includes KRSA-028 is a next-generation shuttled antibody targeting amyloid beta for the treatment of Alzheimer's disease. Korsana Biosciences Inc. is based in WALTHAM, Mass.
| Revenue (Most Recent Fiscal Year) | $2.07M |
| Net Income (Most Recent Fiscal Year) | $-3.53M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 687.51 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.12 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -353.00% |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -87.96% |
| Return on Assets (Trailing 12 Months) | -74.86% |
| Current Ratio (Most Recent Fiscal Quarter) | 0.82 |
| Quick Ratio (Most Recent Fiscal Quarter) | 0.82 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $16.20 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-2.87 |
| Earnings per Share (Most Recent Fiscal Year) | $-7.77 |
| Diluted Earnings per Share (Trailing 12 Months) | $-11.62 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 45.54M |
| Free Float | 31.41M |
| Market Capitalization | $1.43B |
| Average Volume (Last 20 Days) | 0.13M |
| Beta (Past 60 Months) | 1.72 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 31.04% |
| Percentage Held By Institutions (Latest 13F Reports) | 75.62% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |